286 related articles for article (PubMed ID: 21816968)
1. Auger electron radioimmunotherapeutic agent specific for the CD123+/CD131- phenotype of the leukemia stem cell population.
Leyton JV; Hu M; Gao C; Turner PV; Dick JE; Minden M; Reilly RM
J Nucl Med; 2011 Sep; 52(9):1465-73. PubMed ID: 21816968
[TBL] [Abstract][Full Text] [Related]
2. MicroSPECT/CT imaging of primary human AML engrafted into the bone marrow and spleen of NOD/SCID mice using 111In-DTPA-NLS-CSL360 radioimmunoconjugates recognizing the CD123+ / CD131- epitope expressed by leukemia stem cells.
Leyton JV; Williams B; Gao C; Keating A; Minden M; Reilly RM
Leuk Res; 2014 Nov; 38(11):1367-73. PubMed ID: 25278187
[TBL] [Abstract][Full Text] [Related]
3. The human polynucleotide kinase/phosphatase (hPNKP) inhibitor A12B4C3 radiosensitizes human myeloid leukemia cells to Auger electron-emitting anti-CD123 ¹¹¹In-NLS-7G3 radioimmunoconjugates.
Zereshkian A; Leyton JV; Cai Z; Bergstrom D; Weinfeld M; Reilly RM
Nucl Med Biol; 2014; 41(5):377-83. PubMed ID: 24637100
[TBL] [Abstract][Full Text] [Related]
4. Auger electron-emitting (111)In-DTPA-NLS-CSL360 radioimmunoconjugates are cytotoxic to human acute myeloid leukemia (AML) cells displaying the CD123(+)/CD131(-) phenotype of leukemia stem cells.
Gao C; Leyton JV; Schimmer AD; Minden M; Reilly RM
Appl Radiat Isot; 2016 Apr; 110():1-7. PubMed ID: 26748017
[TBL] [Abstract][Full Text] [Related]
5. Paradoxical effects of Auger electron-emitting (111)In-DTPA-NLS-CSL360 radioimmunoconjugates on hCD45(+) cells in the bone marrow and spleen of leukemia-engrafted NOD/SCID or NRG mice.
Bergstrom D; Leyton JV; Zereshkian A; Chan C; Cai Z; Reilly RM
Nucl Med Biol; 2016 Oct; 43(10):635-41. PubMed ID: 27497632
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.
Jin L; Lee EM; Ramshaw HS; Busfield SJ; Peoppl AG; Wilkinson L; Guthridge MA; Thomas D; Barry EF; Boyd A; Gearing DP; Vairo G; Lopez AF; Dick JE; Lock RB
Cell Stem Cell; 2009 Jul; 5(1):31-42. PubMed ID: 19570512
[TBL] [Abstract][Full Text] [Related]
7. Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences.
Kersemans V; Cornelissen B; Minden MD; Brandwein J; Reilly RM
J Nucl Med; 2008 Sep; 49(9):1546-54. PubMed ID: 18703602
[TBL] [Abstract][Full Text] [Related]
8. ¹¹¹In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer.
Fasih A; Fonge H; Cai Z; Leyton JV; Tikhomirov I; Done SJ; Reilly RM
Breast Cancer Res Treat; 2012 Aug; 135(1):189-200. PubMed ID: 22736376
[TBL] [Abstract][Full Text] [Related]
9. Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells.
Chen P; Wang J; Hope K; Jin L; Dick J; Cameron R; Brandwein J; Minden M; Reilly RM
J Nucl Med; 2006 May; 47(5):827-36. PubMed ID: 16644753
[TBL] [Abstract][Full Text] [Related]
10. CD16
Williams BA; Wang XH; Leyton JV; Maghera S; Deif B; Reilly RM; Minden MD; Keating A
Haematologica; 2018 Oct; 103(10):1720-1729. PubMed ID: 29976748
[TBL] [Abstract][Full Text] [Related]
11. A radiolabeled antibody targeting CD123(+) leukemia stem cells - initial radioimmunotherapy studies in NOD/SCID mice engrafted with primary human AML.
Leyton JV; Gao C; Williams B; Keating A; Minden M; Reilly RM
Leuk Res Rep; 2015; 4(2):55-9. PubMed ID: 26500848
[TBL] [Abstract][Full Text] [Related]
12. (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.
Costantini DL; Chan C; Cai Z; Vallis KA; Reilly RM
J Nucl Med; 2007 Aug; 48(8):1357-68. PubMed ID: 17631548
[TBL] [Abstract][Full Text] [Related]
13. ChAcNLS, a Novel Modification to Antibody-Conjugates Permitting Target Cell-Specific Endosomal Escape, Localization to the Nucleus, and Enhanced Total Intracellular Accumulation.
Beaudoin S; Rondeau A; Martel O; Bonin MA; van Lier JE; Leyton JV
Mol Pharm; 2016 Jun; 13(6):1915-26. PubMed ID: 27112376
[TBL] [Abstract][Full Text] [Related]
14. AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells.
Fan D; Li Z; Zhang X; Yang Y; Yuan X; Zhang X; Yang M; Zhang Y; Xiong D
J Hematol Oncol; 2015 Feb; 8():18. PubMed ID: 25879549
[TBL] [Abstract][Full Text] [Related]
15. 111In- or 99mTc-labeled recombinant VEGF bioconjugates: in vitro evaluation of their cytotoxicity on porcine aortic endothelial cells overexpressing Flt-1 receptors.
Chan C; Cai Z; Su R; Reilly RM
Nucl Med Biol; 2010 Feb; 37(2):105-15. PubMed ID: 20152709
[TBL] [Abstract][Full Text] [Related]
16. CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection.
Al-Mawali A; Pinto AD; Al-Zadjali S
Acta Haematol; 2017; 138(3):175-181. PubMed ID: 29065396
[TBL] [Abstract][Full Text] [Related]
17. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.
Mardiros A; Dos Santos C; McDonald T; Brown CE; Wang X; Budde LE; Hoffman L; Aguilar B; Chang WC; Bretzlaff W; Chang B; Jonnalagadda M; Starr R; Ostberg JR; Jensen MC; Bhatia R; Forman SJ
Blood; 2013 Oct; 122(18):3138-48. PubMed ID: 24030378
[TBL] [Abstract][Full Text] [Related]
18. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
[TBL] [Abstract][Full Text] [Related]
19. Targeting primary human Ph(+) B-cell precursor leukemia-engrafted SCID mice using radiolabeled anti-CD19 monoclonal antibodies.
Mitchell P; Lee FT; Hall C; Rigopoulos A; Smyth FE; Hekman AM; van Schijndel GM; Powles R; Brechbiel MW; Scott AM
J Nucl Med; 2003 Jul; 44(7):1105-12. PubMed ID: 12843229
[TBL] [Abstract][Full Text] [Related]
20. Development of a new anti-CD123 monoclonal antibody to target the human CD123 antigen as an acute myeloid leukemia cancer stem cell biomarker.
Abdollahpour-Alitappeh M; Razavi-Vakhshourpour S; Abolhassani M
Biotechnol Appl Biochem; 2018 Nov; 65(6):841-847. PubMed ID: 29972607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
